Stock Research for CLDX

CLDX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CLDX Stock Chart & Research Data

The CLDX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CLDX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CLDX Due diligence Resources & Stock Charts

The CLDX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CLDX Detailed Price Forecast - CNN Money CNN View CLDX Detailed Summary - Google Finance
Yahoo View CLDX Detailed Summary - Yahoo! Finance Zacks View CLDX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CLDX Trends & Analysis - Trade-Ideas Barrons View CLDX Major Holders - Barrons
NASDAQ View CLDX Call Transcripts - NASDAQ Seeking View CLDX Breaking News & Analysis - Seeking Alpha
Spotlight View CLDX Annual Report - CompanySpotlight.com OTC Report View CLDX OTC Short Report - OTCShortReport.com
TradeKing View CLDX Fundamentals - TradeKing Charts View CLDX SEC Filings - Bar Chart
WSJ View Historical Prices for CLDX - The WSJ Morningstar View Performance/Total Return for CLDX - Morningstar
MarketWatch View the Analyst Estimates for CLDX - MarketWatch CNBC View the Earnings History for CLDX - CNBC
StockMarketWatch View the CLDX Earnings - StockMarketWatch MacroAxis View CLDX Buy or Sell Recommendations - MacroAxis
Bullish View the CLDX Bullish Patterns - American Bulls Short Pains View CLDX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CLDX Stock Mentions - StockTwits PennyStocks View CLDX Stock Mentions - PennyStockTweets
Twitter View CLDX Stock Mentions - Twitter Invest Hub View CLDX Investment Forum News - Investor Hub
Yahoo View CLDX Stock Mentions - Yahoo! Message Board Seeking Alpha View CLDX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CLDX - SECform4.com Insider Cow View Insider Transactions for CLDX - Insider Cow
CNBC View CLDX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CLDX - OTC Markets
Yahoo View Insider Transactions for CLDX - Yahoo! Finance NASDAQ View Institutional Holdings for CLDX - NASDAQ


Stock Charts

FinViz View CLDX Stock Insight & Charts - FinViz.com StockCharts View CLDX Investment Charts - StockCharts.com
BarChart View CLDX Stock Overview & Charts - BarChart Trading View View CLDX User Generated Charts - Trading View




Latest Financial News for CLDX


Celldex Presents Emerging MerTK Antibody Program at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
Posted on Saturday November 10, 2018

Celldex Therapeutics, Inc. (CLDX) presented data from the Company’s MerTK antibody program in a poster session today at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting. MerTK is emerging as a promising target for cancer immunotherapy. Its expression in innate immune cells is believed to negatively regulate immune responses and genetic removal of MerTK renders mice resistant to some tumors.


Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss
Posted on Friday November 09, 2018

Celldex (CLDX) reports narrower-than-expected loss in Q3. Revenues fall on reduced contract revenues and also miss estimates.


Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
Posted on Friday November 09, 2018

Celldex Therapeutics, Inc. (CLDX) presented interim data today from the Phase 1 dose-escalation study of CDX-1140, a fully human agonist anti-CD40 antibody. CD40, expressed on dendritic cells and other antigen presenting cells, has long been an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses. “We have completed four of the potential eight monotherapy dose levels and, to date, CDX-1140 has been well tolerated.


Here's Why Celldex Therapeutics, Inc. Surged on Thursday
Posted on Thursday November 08, 2018

The company's third-quarter earnings report gave investors lots to look forward to.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.